ORAL PROGRAM

SUNDAY OCTOBER 27, 2019

08:00-19:00	**REGISTRATION**	***(Minneplein)***
09:00-10:00	**WELCOME COFFEE** (SPONSORED BY *GSK*)	***(Minneplein)***
10:00-10:10	**OPENING REMARKS** **ISV Congress co-Chairs: Linda Klavinskis**, *Kings College London*; **Ted Ross,** *University of Georgia*; **Xavier Saelens,** *University of Ghent*	***(Auditorium)***
10:10-12:00	**OPENING SESSION** **PLENARY SESSION 1: Emerging Infectious/Neglected Diseases – Are We Making Progress?** **Session Chairs: David Weiner,** *Wistar Institute*; **Linda Klavinskis,** *King's College London*	***(Auditorium)***
10:10-10:45	**KEYNOTE SPEAKER** **Creating a world in which epidemics are no longer a threat to humanity: the challenges of developing vaccines in the 21st Century** Luc Debruyne**,** *Coalition for Epidemic Preparedness Innovations (CEPI)*	
10:45-11:10	**[PL1.1] Rapid emerging infectious disease response utilizing a measles vaccine vector platform** Katrin Ramsauer, *Themis Bioscience GmbH*	
11:10-11:35	**[PL1.2] Viral Vectors as a Platform Technology for Emerging Pathogen Vaccines** Sarah Gilbert, *Jenner Institute*	
11:35-12:00	**[PL1.3] Recent Advances in Tuberculosis Vaccine Development** Ann Ginsberg, *IAVI*	
12:00-13:30	**LUNCH** (SPONSORED BY *IMBCAMS*)	***(Banquet Room)***
13:30-15:05	**PLENARY SESSION 2: Personalized Cancer Vaccines - Why Being Different is Good** **Session Chairs: Annie DeGroot,** *EpiVax;* **Jeffrey Ulmer,** *GlaxoSmithKline (GSK)*	***(Auditorium)***
13:30-13:55	**[PL2.1] Development of neoantigen-specific cancer vaccines: From prediction of neoantigens to development of a potent vaccine** Karin Jooss, *Gritstone Oncology, Inc.*	
13:55-14:20	**[PL2.2] Discovery of actionable tumor antigens presented by MHC class I molecules** Claude Perreault, *Université de Montréal*	
14:20-14:35	**[PL2.3] Nouscom personalized and off-the-shelf vaccines encoding many cancer neoantigens to cure large solid tumors, in combination with checkpoint inhibitors** Maria Teresa Catanese, *Nouscom SRL*	
14:35-14:50	**[PL2.4] Active immunization with PD1-derived B cell mimotope - New strategies in cancer immunotherapy against Her-2/neu-expressing tumors** Joshua Tobias, *Medical University of Vienna*	
14:50-15:05	**[PL2.5] In vivo expression of plasmid encoded IgG for immune check point targets by synthetic enhanced DNA as a new tool for cancer immunotherapy** Kar Muthumani, *The Wistar Institute*	
15:05- 15:35	**COFFEE BREAK** (SPONSORED BY *PFIZER*)	***(Minneplein)***

15:35-17:55	**CONCURRENT SESSION 1** ***(Room Jan Van Eyck)*** **Structural and Computational Vaccine Design** **Session Chairs:** **Xavier Saelens** *University of Ghent* **Lenny Moise** *University of Rhode Island*	**CONCURRENT SESSION 2** ***(Room Hubert Van Eyck)*** **What's New in Vaccine Formulations and Delivery** **Session Chairs:** **Anna-Lise Williamson** *University of Capetown* **Karl Ljungberg** *Eurocine Vaccines*	**CONCURRENT SESSION 3A** ***(Room Van der Goes)*** **HCMV Vaccines – Current Status & Future Projects** **Session Chair:** **Stanley Plotkin** *VaxConsult LLC*

15:35-16:00	**[O1.1]** **Trivalent cocktail of de novo designed immunogens enables the robust induction and focusing of functional antibodies in vivo** Bruno Correia *Laboratory of Protein Design & Immunoengineering (LPDI)*	**[O2.1]** **Polymeric adjuvants for enhanced vaccine induced cellular immunity** Ed Lavelle *Trinity College Dublin*	**[O3.1]** **Prospects for Vaccination Against Cytomegalovirus** Stanley Plotkin *Vaxconsult LLC* →15:35-15:55←
16:00-16:25	**[O1.2]** **Making use of human monoclonal antibodies for the prevention and treatment of viral diseases** Davide Corti *Institute for Research in Biomedicine (IRB)*	**[O2.2]** **Composite Virus-like particles (VLP) by constructing intelligent artificial nano/micro "chassis" assembled with antigens** Guanghui Ma *Chinese Academy of Sciences (CAS)*	**[O3.2]** **CMV: State-of-the-art approach to prophylaxis** Fabienne Piras-Douce *Sanofi Pasteur* →15:55-16:15←
16:25-16:40	**[O1.3]** **Immunogenicity of ultrastable HIV-1 native-like envelope trimers** Ivan del Moral Sánchez *Amsterdam UMC, Academic Medical Center*	**[O2.3]** **Bridging systemic and gastrointestinal immune responses for enhanced vaccinations** Yufei Xia *Chinese Academy of Sciences (CAS)*	**[O3.3]** **Clinical Immunogenicity Profile of Cytomegalovirus Vaccine V160** Dai Wang *Merck* →16:15-16:35←
16:40-16:55	**[O1.4]** **Co-display of hyperstabilized HIV-1 envelope glycoprotein trimers on two-component protein nanoparticles** Mitch Brinkkemper *Amsterdam UMC*	**[O2.4]** **Microneedle vaccination against Zika virus confers enhanced cellular and humoral immunity while protecting immune privileged compartments** Ioanna Skountzou *Emory University*	**[O3.4]** **Development of a subunit based CMV vaccine** Kirsten Schneider-Ohrum *GSK* →16:35-16:55←
16:55-17:10	**[O1.5]** **Innovative HIV-1 Nanovaccine Adjuvanted with Army Liposome Formulation: Glycosylated V1V2 Envelope Proteins Displayed on a Self-Assembling Protein Nanoparticle** Zoltan Beck *Walter Reed Army Institute of Research* *Henry M Jackson Foundation*	**[O2.5]** **Th17-polarizing mucosal CTA1-DD adjuvant generates highly protective CD4 T-cell responses when used in combination with a universal flu vaccine candidate** Li Ching Ong *University of Gothenburg*	**[O3.5]** **Vaccine efficacy against genital HSV-1 and HSV-2 infection and immune correlates of protection for an HSV-2 gC2/gD2/gE2 trivalent nucleoside-modified mRNA-LNP vaccine for genital herpes** Harvey Friedman *University of Pennsylvania* →16:55-17:10←
17:10-17:25	**[O1.6]** **Reconstitution of a Dengue virus neutralizing epitope** Chen Piller *Tel Aviv University*	**[O2.6]** **A built-in adjuvant-engineered mucosal vaccine against Fusobacterium nucleatum and Porphyromonas gingivalis inhibits dysbiotic periodontal diseases in a mouse model** Joon Haeng Rhee *Chonnam National University*	**CONCURRENT SESSION 3B** ***(Room Van der Goes)*** **Emerging Infectious Disease Vaccines: Clinical Studies** **Session Chair:** **Sarah Gilbert** *Oxford University*

17:25-17:40	**[O1.7]** **Dengue and Zika virus domain III-flagellin fusion and glycan-masking E antigen for prime-boost vaccine immunization** Suh Chin Wu *Institute of Biotechnology* *National Tsing Hua University*	**[O2.7]** **TriMix based mRNA immunotherapies** Stefaan De Koker *eTheRNA immunotherapies*	**[O3.6]** **Ad26.ZIKV.001 induces durable humoral immune responses in humans that confer high levels of passive protection in a murine Zika virus challenge model** Nadine Salisch *Janssen Vaccines B.V.* →17:10-17:25←
17:40-17:55	**[O1.8]** **Presenting novel soluble hepatitis C virus E1E2 glycoproteins on a designed two-component nanoparticle to enhance immunogenicity** Kwinten Sliepen *Amsterdam UMC* *University of Amsterdam*	**[O2.8]** **Mucosal immunity induced by the intranasal delivery/adjuvant NanoVaxTM -formulated vaccine protected animals from respiratory and genital infections. A promising path to improving efficacy of existing vaccines and developing a past overdues ones.** Ali Fattom *Bluewillow Biologics*	**[O3.7]** **Development of a single-shot live-attenuated Chikungunya vaccine: A Phase 1 randomized clinical trial in healthy adults.** Nina Wressnigg *Valneva Austria* →17:25-17:40←
			[O3.8] **A synthetic, consensus DNA vaccine against Middle East Respiratory Syndrome coronavirus (MERS-CoV), GLS-5300, induces robust humoral and cellular immune responses in humans** Emma Reuschel *The Wistar Institute* →17:40-17:55←
17:55-19:00	**POSTER SESSION # 1**		***(Minneplein)***
18:30-20:00	**WELCOME RECEPTION** (SPONSORED BY *EPIVAX*)		***(Minneplein)***

MONDAY OCTOBER 28, 2019			
07:30-08:00	**MORNING COFFEE** (SPONSORED BY *HIVF*)		***(Minneplein)***
08:00-09:45	**PLENARY SESSION 3: <u>Influence of the Microbiome Shaping the Immune Response to Vaccines</u>** ***(Auditorium)*** **Session Chairs: Beate Kampmann,** *London School. of Hygiene and Tropical Medicine (LSHTM)* **Margaret Liu,** *ProTherImmune*		
08:00-08:25	**[PL3.1] Modulation of Host Immunity by Targeting Gut Microbiota** Sin-Hyeog Im, *Pohang University of Science and Technology (POSTECH)*		
08:25-08:50	**[PL3.2] The Microbiome and HIV Vaccine Response Heterogeneity** James Kublin, *Fred Hutchinson Cancer Research Center*		
08:50-09:15	**[PL3.3] The intestinal microbiota and oral vaccine immunogenicity** Nick Grassly, *Imperial College London*		
09:15-09:30	**[PL3.4] Impact of the gut microbiota on rotavirus vaccine response in Indian, African and European infants: a prospective cohort study** Edward Parker, *London School of Hygiene and Tropical Medicine (LSHTM)*		
09:30-09:45	**[PL3.5] Two-year Follow-up Results of an Extra-Intestinal Pathogenic E. Coli Vaccine in Healthy Adults: ESTELLA, a Phase 2 Randomized Study** Wouter Haazen, *Janssen Research & Development*		
09:45-10:15	**COFFEE BREAK** (SPONSORED BY *JANSSEN*)		***(Minneplein)***
10:15-12:20	**CONCURRENT SESSION 4** ***(Room Jan Van Eyck)*** **<u>Vaccines for Respiratory Infections</u>** **Session Chairs:** **John Oxford** *Queen Mary College* **Stephen Kent** *Doherty Institute*	**CONCURRENT SESSION 5** ***(Room Hubert Van Eyck)*** **<u>HIV Vaccines – Are We Making Progress?</u>** **Session Chairs:** **Jerome Kim** *International Vaccine Institute* **Hanneke Schuitemaker** *Jansen Vaccines & Prevention*	**CONCURRENT SESSION 6** ***(Room Van der Goes)*** **<u>Third Generation Vaccines (RNA & DNA Vaccines)</u>** **Session Chairs:** **Maria Issagouliantis** *Karolinska Institute* **Shan Lu** *UMASS Medical School*
10:15-10:40	**[O4.1]** **The current TB vaccine pipeline and the TB Vaccine Development Pathway** Gerald Voss *Tuberculosis Vaccine Initiative (TBVI)*	**[O5.1]** **Cleavage-independent HIV-1 Env trimers elicit cross-neutralizing antibodies at multiple sites of vulnerability** Richard Wyatt *The Scripps Research Institute*	**[O6.1]** **A novel DNA vaccine aiming to quench emerging pandemic threats** Gunnveig Grødeland *University of Oslo*
10:40-11:05	**[O4.2]** **Augmented germinal center formation underpins enhanced immunogenicity of self-assembling protein nanoparticle vaccines for influenza** Stephen Kent *University of Melbourne*	**[O5.2]** **Advancing a global HIV vaccine candidate through the development pipeline** Hanneke Schuitemaker *Janssen Vaccines & Prevention*	**[O6.2]** **Infectious RNA vaccine protects against Chikungunya virus infection** Karl Ljungberg *Eurocine Vaccines* →10:40-10:55←
11:05-11:20	**[O4.3]** **Respiratory Infection Vaccines** Natalie Mazur *UMC Utrecht*	**[O5.3]** **Aiming for protective T-cell responses: A focus on the conserved regions of the HIV-1** Tomas Hanke *University of Oxford*	**[O6.3]** **Development of a dual-target rabies/yellow fever vaccine candidate** Kai Dallmeier *KU Leuven* →10:55-11:10←

11:20-11:35	**[O4.4]** **Memory B-cell recall responses following quadrivalent influenza vaccination** Rodrigo Abreu *Center for Vaccines and Immunology* *University of Georgia*	**[O5.4]** **Comparison of monoclonal antibodies induced by HIV-1 envelop glycoprotein immunization and SHIV infection in non-human primates** Jelle van Schooten *Amsterdam UMC* *University of Amsterdam*	**[O6.4]** **Efficacy of a subunit DNA vaccine adjuvanted with 7HP349, an integrin activator, in controlling Trypanosoma cruzi infection** Nisha Garg *University of Texas Medical Branch* →11:10-11:25←
11:35-11:50	**[O4.5]** **An H1N1 COBRA-based influenza vaccine strategy elicits unique potent broadly neutralizing antibodies against hemagglutinin** Giuseppe Andrea Sautto *Center for Vaccines and Immunology* *University of Georgia*	**[O5.5]** **Pre-clinical and Clinical Development of HIV-1 Envelope Designs Expressed in a Replication Competent Ad4 Vector for Intranasal Administration** Mark Connors *NIAID*	**[O6.5]** **Development of a potent Synthetic DNA vaccine targeting Lyme disease** Trevor Smith *Inovio Pharmaceuticals* →11:25-11:40←
11:50-12:05	**[O4.6]** **Antibodies targeting the RSV SH or influenza M2 proteins engage macrophages to take up infected cells.** Bert Schepens *Ghent University and VIB*	**[O5.6]** **Low-level HIV Gag-p24 antigen persistence in the lymph nodes of Fiebig stage I treated HIV-infected individuals correlates with efficient GCTfh help to B cells** Omolara Baiyegunhi *Africa Health Research Institute*	**[O6.6]** **A Single Amino Acid Change Impacts the Immunogenicity and Efficacy of Modified mRNA-Based Zika Vaccines in Pre-Clinical Animal Models** Kapil Bahl *Moderna* →11:40-11:55←
12:05-12:20	**[O4.7]** **Influenza virus infection and immunization induces high titer cross-reactive HA-specific ADP and monocyte infection-enhancing responses in macaques** Gerrit Koopman *Biomedical Primate Research Centre*	**[O5.7]** **SHIV162P3 transmission by semen leukocytes is efficiently inhibited by a combination of broad neutralizing antibodies** Mariangela Cavarelli *CEA*	**[O6.7]** **Impact of vaccine-induced anti-V2 antibodies on virus control in SHIVBaL.P4 challenged rhesus macaques** Miroslaw Gorny *New York University School of Medicine* →11:55-12:10←
12:20-13:30	**LUNCH** (SPONSORED BY *GLOBAL HIV VACCINE ENTERPRISE*)		***(Banquet Room)***
13:30-15:00	**POSTER SESSION 2**		***(Minneplein)***
14:00-15:00	**ISV ANNUAL GENERAL MEETING**		***(Jan Van Eyck)***
15:00-15:30	**COFFEE BREAK** (SPONSORED BY *THE NATIVE ANTIGEN COMPANY)*		***(Minneplein)***
15:30-17:35	**PLENARY SESSION 4: Profiling the Immune Response to Vaccination During the Life Course – Why Age and Route of Immunization Matters**		***(Auditorium)***
	Session Chairs: Denise Doolan, *James Cook University*; **Adrian McDermott,** *NIAID/NIH*		
15:30-15:55	**[PL4.1] Vaccination in the context of immune ontogeny** Beate Kampmann, *London School of Hygiene & Tropical Medicine (LSHTM)*		
15:55-16:20	**[PL4.2] Preventing pneumococcal infections from birth to just before the grave** David Goldblatt, *Institute of Child Health, University College London*		

16:20-16:35	**[PL4.3] Inactivated poliovirus adjuvants the innate response to acellular pertussis booster vaccination via TLR8 sensing on myeloid dendritic cells and non-classical monocytes** Joshua Gillard, *Radboud University Medical Center*
16:35-16:50	**[PL4.4] Maternal immunization- An update where we stand with protecting neonates and young infants from infectious diseases** Kathrin Jansen, *Pfizer Inc*
16:50-17:05	**[PL4.5] Immune system development varies according to age, location and anemia in African children** Danika Hill, *Babraham Institute*
17:05-17:20	**[PL4.6] Harnessing innate immune memory induced by vaccine prime : timing and route of administration matter** Yanis Feraoun, *CEA Paris-Saclay*
17:20-17:35	**[PL4.7] The route of vaccine administration affects early immunity with consequences on the quality of the long-term response** Frederic Martinon, *CEA - Université Paris Sud 11 - Inserm U1184*
17:50-18:10	**BUS PICK UP FOR GALA DINNER**
18:30-22:00	**GALA DINNER** (SPONSRED BY *VGXI* AND *IMBCAMS*) ***TICKETS REQUIRED***

TUESDAY OCTOBER 29, 2019			
07:30-08:00	**MORNING COFFEE** (SPONSORED BY *TAYLOR & FRANCIS*) ***(Minneplein)***		
08:00-10:00	**PLENARY SESSION 5: Next Generation Tools and Technologies for Vaccine Development** ***(Auditorium)*** **Session Chairs: Jonathan Gershoni,** *Tel Aviv University;* **Kathrin Jansen,** *Pfizer, Inc*		
08:00-08:25	**[PL5.1] Immunogenetic analyses of B cell responses following influenza immunization** Adrian McDermott, *NIH*		
08:25-08:50	**[PL5.2] Preparing for Disease X: Developing a Rapid Response Vaccine Pipeline** Paul Young, *University of Queensland*		
08:50-09:05	**[PL5.3] High-throughput mapping of B-cell receptor sequence to antigen specificity** Ian Setliff, *Vanderbilt University Medical Center*		
09:05-09:20	**[PL5.4] Modulation of Burkholderia pseudomallei Immune Responses by Human-like T cell Epitopes have Implications for Vaccine Design** Lenny Moise, *Epivax, Inc.*		
09:20-09:35	**[PL5.5] Proteome-wide screening identifies novel Plasmodium antigens which are effective targets of cross-species protective immunity against malaria** Denise Doolan, *James Cook University*		
09:35-09:50	**[PL5.6] Using Plants to Make a Decavalent Human Papillomavirus Virus-Like Particle Vaccine Candidate** Edward Rybicki, *Biopharming Research Unit, University of Cape Town*		
09:50-10:20	**COFFEE BREAK** (SPONSORED BY *VALNEVA AUSTRIA GmbH*) ***(Minneplein)***		
10:20-11:40	**CONCURRENT SESSION 7** ***(Room Jan Van Eyck)*** **Emerging Infectious Diseases Vaccines: Pre-Clinical, Are We Making Progress?** **Session Chairs:** **Randy Albrecht** *Icahn School of Medicine at Mt. Sinai* **Gary Kobinger** *Research Centre on Infectious Diseases, Université Laval*	**CONCURRENT SESSION 8** ***(Room Hubert Van Eyck)*** **Viral Vaccine Vectors** **Session Chairs:** **Antonella Folgori** *Okairos* **Frederick Tangy** *Institute Pasteur*	**CONCURRENT SESSION 9** ***(Room Van der Goes)*** **★Bright Sparks in Vaccinology★ (Junior Researcher Session)** **Session Chairs:** **Linda Klavinskis,** *King's College London* **Joon Haeng Rhee,** *Chonnam National University*
10:20-10:45	**[O7.1]** **A hundred Intradermal injections of vaccine per second evaluated against Ebola, CCHF and HIV** Gary Kobinger *Research Centre on Infectious Diseases, Université Laval*	**[O8.1]** **Vaccination with recombinant measles virus vaccine controls SHIV infection and strongly reduces reservoir establishment in macaques** Frederick Tangy *Institut Pasteur - CNRS*	**[O9.1]** **Systems vaccinology of YF17D immunization in mice** Ji Ma *KU Leuven* →10:20-10:30←
10:45-11:00	**[O7.2]** **Effect of vaccine vectors on antibody responses to Ebola virus glycoprotein in non-human primates: Can Ebola vaccines have universal immune correlates of protection?** Alexander Bukreyev *University of Texas Medical Branch at Galveston, Galveston National Laboratory*	**[O8.2]** **Development of Single Dose Vaccines against Emerging and Reemerging Infectious Diseases Using a Novel MVA-VLP Vector** Farshad Guirakhoo *GeoVax, Inc.*	**[O9.2]** **Potent immunogenicity and protective efficacy of a multi-pathogen vaccine targeting Filoviruses and an Arenavirus.** Hannah Sharpe *University of Oxford* →10:30-10:40←

11:00-11:15	**[O7.3]** **NS1 DNA vaccination protects against Zika infection through T cell mediated immunity in immunocompetent mice** Branka Grubor-Bauk *University of Adelaide*	**[O8.3]** **A gorilla adenovirus-based vaccine against Zika virus confers protection in immunocompromised and immunocompetent mouse pregnancy models** Ahmed Hassan *Washington University in St. Louis*	**[O9.3]** **The effect of individual differences of vaccine recipients on the humoral immune response after the second primary immunization with inactivated tick-borne encephalitis vaccines based on the far eastern viral strains** Liubov Chernokhaeva *FSBSI* *Chumakov FSC IBP RAS* →10:40-10:50←
11:15-11:30	**[O7.4]** **A Chimeric Live-attenuated Zika/Japanese encephalitis Virus (ZIK-JEprM/E) Vaccine Protects Against Both JEV and ZIKV** Niraj Mishra *KU Leuven*	**[O8.4]** **Preclinical immunogenicity evaluation of a therapeutic hepatitis B vaccine candidate based on chimpanzee adenoviral vector / MVA vector prime-boost regimen, administered with AS01 adjuvanted HBc-HBs proteins in the AAV-HBV-transduced HLA-A2/DR1 mouse model.** Babak Bayat *GSK*	**[O9.4]** **Single dose vaccination with a hepatotropic Adeno-associated virus (AAV) efficiently localises T cell immunity in the liver with the potential to confer rapid protection against hepatitis C virus (HCV)** Makutiro Masavuli *University of Adelaide* →10:50-11:00←
11:30-11:45	**[O7.5]** **Intradermal vaccine INO-4700 is dose-sparing and prevents against disease in Middle East Respiratory Syndrome coronavirus (MERS-CoV) infected rhesus macaques** Ami Patel *The Wistar Institute*	**[O8.5]** **Army Liposome Formulations Induce Durable Binding and Functional Antibody Responses to HIV-1 Envelope gp120 Protein** Mangala Rao *USMHRP, Walter Reed Army Institute of Research*	**[O9.5]** **Infection-permissive immunity against influenza virus provided by vaccination prevents loss of alveolar macrophages and modulates virus-induced cross-reactive immune responses during subsequent influenza infections.** Angela Choi *Icahn School of Medicine at Mount Sinai* →11:00-11:10←
			[O9.6] **Using an aerosol human BCG infection model in healthy, BCG-naïve, UK adults to define the early innate immune response in the lung and systemic circulation** Julia Marshall *Jenner Institute, The University of Oxford* →11:10-11:20←

			[O9.7] **Next Generation COBRA hemagglutinin-based vaccines elicits broadly reactive antibodies against a panel of H5Nx viruses** Ivette Nunez *University of Georgia* →11:20-11:30←
			[O9.8] **Whole genome sequencing uncovers genome diversity and genetic variation in neonatal invasive GBS isolates of the same clonal group** Sindiswa Lukhele *Respiratory and Meningeal Pathogens Research Unit* →11:30-11:40←
11:45-12:45	**LUNCH** (SPONSORED *BY INOVIO PHARMACEUTICALS*)		***(Banquet Room)***
12:30-13:45	**Career Development Panel** Celine Carrat, *EMBO Molecular Medicine*; Ravi Degun, *Navigant Consulting*; Katrin Ramsauer, *Themis Bioscience;* Tom Dyrberg, *Novo Ventures*; Elisabeth Mahase, *The British Medical Journal;* Jan Staelens, *VIB*		***(Jan Van Eyck)***
12:45-13:45	**SESSION 6: LATE BREAKER ORAL ABSTRACTS** **Session Chairs: Pierre van Damme,** *University of Antwerp*		***(Auditorium)***
12:45-13:00	**[LB10.1] Ancer-designed self-amplifying RNA neo-epitope vaccine elicits anti-tumor T cell immunity** Annie DeGroot, *Epivax*		
13:00-13:15	**[LB10.2] Comparison of biological characteristics of HSV2 mutant strain RL1-HSV2, LAT-HSV2, RL1-LAT-HSV2** Lei Liu, *Institute of medical Biology, Chinese Academy of Medical Science and Peking Union Medical College*		
13:15-13:30	**[LB10.3] A novel vaccine targeting the viral protease cleavage sites protects Mauritian cynomolgus macaques against vaginal SIVmac251 infection** Ma Luo, *The Public Health Agency of Canada, PHAC/ASPC*		
13:30-13:45	**[LB10.4] Assessment of Antibody Functional Affinity using ImmunSpot®** Greg Kirchenbaum, *Cellular Technology Limited*		
13:50-14:00	**ISV Award Ceremony**		***(Auditorium)***
14:00-15:30	**CLOSING SESSION 7: Walking Towards the End Game for Disease Eradication** **Session Chair: Ted Ross,** *University of Georgia*		***(Auditorium)***
14:00-14:25	**[CL7.1] Walking Towards the End Game for Poliomyelitis Eradication: development of a new oral polio vaccine** Pierre Van Damme, *University of Antwerp*		
14:25-14:50	**[CL7.2] Is Africa missing opportunities for delivering life-saving vaccines to her children?** Charles Shey Wiysonge, *South African Cochrane Centre*		
14:50-15:15	**[CL7.3] Access to Vaccines: cases studies in impediments to vaccination** Jerome Kim, *International Vaccine Institute*		
15:15-15:30	**CLOSING REMARKS AND INTRODUCTION TO 2020 CONGRESS**		***(Auditorium)***